GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Cyclically Adjusted Price-to-FCF

Diamyd Medical AB (FRA:DMN) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Diamyd Medical AB Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Diamyd Medical AB's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Cyclically Adjusted Price-to-FCF Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Diamyd Medical AB Quarterly Data
May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Diamyd Medical AB's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Diamyd Medical AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Cyclically Adjusted Price-to-FCF falls into.


;
;

Diamyd Medical AB Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Diamyd Medical AB's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2025 is calculated as:

For example, Diamyd Medical AB's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Feb. 2025 (Change)*Current CPI (Feb. 2025)
=-0.042/133.7436*133.7436
=-0.042

Current CPI (Feb. 2025) = 133.7436.

Diamyd Medical AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201505 -0.019 100.285 -0.025
201508 -0.014 99.829 -0.019
201511 -0.018 100.129 -0.024
201602 -0.018 100.253 -0.024
201605 -0.015 100.914 -0.020
201608 -0.012 100.968 -0.016
201611 -0.016 101.517 -0.021
201702 -0.018 102.037 -0.024
201705 -0.018 102.679 -0.023
201708 -0.020 103.138 -0.026
201711 -0.021 103.413 -0.027
201802 -0.019 103.678 -0.025
201805 -0.016 104.632 -0.020
201808 -0.015 105.197 -0.019
201811 -0.018 105.443 -0.023
201902 -0.012 105.641 -0.015
201905 -0.012 106.895 -0.015
201908 -0.074 106.716 -0.093
201911 -0.008 107.345 -0.010
202002 0.049 106.742 0.061
202005 -0.009 106.882 -0.011
202008 -0.010 107.571 -0.012
202011 -0.022 107.549 -0.027
202102 -0.021 108.190 -0.026
202105 -0.037 108.838 -0.045
202108 -0.074 109.780 -0.090
202111 -0.057 111.069 -0.069
202202 -0.026 112.834 -0.031
202205 -0.043 116.746 -0.049
202208 -0.038 120.573 -0.042
202211 -0.034 123.803 -0.037
202302 -0.034 126.321 -0.036
202305 -0.031 128.034 -0.032
202308 -0.038 129.560 -0.039
202311 -0.031 130.958 -0.032
202402 -0.036 132.046 -0.036
202405 -0.033 132.818 -0.033
202408 -0.026 132.052 -0.026
202411 -0.037 133.000 -0.037
202502 -0.042 133.744 -0.042

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Diamyd Medical AB  (FRA:DMN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Diamyd Medical AB Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Industry
Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines